Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02341638 · ClinicalTrials.gov registry record · Phase 1

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
148
Enrollment target

NCT02341638: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.

NCT02341638 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 148 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02341638, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
148 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.

Primary Outcome

Serious adverse event (SAE) Adverse event (AE) Electrocardiogram (ECG)

Interventions

  • DRUG Placebo
  • DRUG Aspirin
  • DRUG Itraconazole
  • DRUG BMS-986141

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2014-09
Est. Completion 2015-09
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT02341638 record still lists

NCT02341638 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT02341638 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02341638 about?

NCT02341638 is a clinical study titled "Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects". The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.

What is the current status of trial NCT02341638?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2014-09. Estimated completion is 2015-09.

What interventions are being tested in trial NCT02341638?

The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Itraconazole (DRUG), BMS-986141 (DRUG).

Who is sponsoring clinical trial NCT02341638?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02341638's enrollment target sits among peer trials

148 382nd of 2000 higher than 1,614 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00739362 · 148 participants · Phase 2

    Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

  • NCT03161223 · 148 participants · Phase 1

    Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

  • NCT03858231 · 148 participants · Phase 4

    Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery

  • NCT04486352 · 148 participants · Phase 1

    A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02341638, the US trial registry maintained by the National Library of Medicine. NCT02341638 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.